International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Opportunities and Challenges.

Neurol Ther · 2026 · PMC13172151 · PMID 41854800

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an apparent trendno p-value reported

An apparent trend to a higher rate of malignancy in patients randomised to CladT from the CLARITY study caused concern initially [ 23 ].

also in 709 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.